Sputum plasminogen activator inhibitor-1 elevation by oxidative stress-dependent nuclear factor-k B activation in COPD

Chest

Volumn 144, Issue 2, 2013, Pages 515-521

  To, Masako ^a,b   Takagi, Dai ^a   Akashi, Kenichi ^a   Kano, Ichino ^b   Haruki, Kosuke ^b   Barnes, Peter J ^a   Ito, Kazuhiro ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIGARETTE SMOKE; HISTONE DEACETYLASE 2; HYDROGEN PEROXIDE; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ACETYLATION; ADULT; ARTICLE; CELL STRAIN; CELL STRAIN A549; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; FEMALE; GENERAL PRACTICE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; MALE; OUTPATIENT DEPARTMENT; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1 SPUTUM LEVEL; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RNA INTERFERENCE; SMOKING; SPUTUM EXAMINATION; SPUTUM LEVEL; TRANSCRIPTION INITIATION;

EID: 84881521758     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2381     Document Type: Article

References (42)

1. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003; 22 (4): 672-688.
2. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2 (1): 50-60.
3. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung infl ammation in COPD. Eur Respir J. 2006; 28 (1): 219-242.
4. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004; 56 (4): 515-548.
5. Ginsburg D, Zeheb R, Yang AY, et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest. 1986; 78 (6): 1673-1680.
6. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) defi ciency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 1997; 90 (1): 204-208.
7. Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol. 2009; 5 (4): 203-211.
8. Daci E, Verstuyf A, Moermans K, Bouillon R, Carmeliet G. Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen defi-ciency. J Bone Miner Res. 2000; 15 (8): 1510-1516.
9. Daci E, Udagawa N, Martin TJ, Bouillon R, Carmeliet G. The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res. 1999; 14 (6): 946-952.
10. Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med. 2003; 115 (suppl 8A): 62S-68S.
11. Nishiuma T, Sisson TH, Subbotina N, Simon RH. Localization of plasminogen activator activity within normal and injured lungs by in situ zymography. Am J Respir Cell Mol Biol. 2004; 31 (5): 552-558.
12. Wygrecka M, Markart P, Ruppert C, et al. Cellular origin of pro-coagulant and (anti)-fi brinolytic factors in bleomycininjured lungs. Eur Respir J. 2007; 29 (6): 1105-1114.
13. Osterholzer JJ, Christensen PJ, Lama V, et al. PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fi brosis following type II alveolar epithelial cell injury. J Pathol. 2012; 228 (2): 170-180.
14. Xiao W, Hsu YP, Ishizaka A, Kirikae T, Moss RB. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fi brosis, COPD, and asthma infl ammation. Chest. 2005; 128 (4): 2316-2326.
15. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2007. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.org. Accessed August 2008.
16. To M, Ito K, Ausin PM, Kharitonov SA, Barnes PJ. Osteoprotegerin in sputum is a potential biomarker in COPD. Chest. 2011; 140 (1): 76-83.
17. Ding L, Quinlan KB, Elliott WM, et al. A lung tissue bank for gene expression studies in chronic obstructive pulmonary disease. COPD. 2004; 1 (2): 191-204.
18. To M, Yamamura S, Akashi K, Charron CE, Barnes PJ, Ito K. Defect of adaptation to hypoxia in patients with COPD due to reduction of histone deacetylase 7. Chest. 2012; 141 (5): 1233-1242.
19. Ito K. Impact of post-translational modifi cations of proteins on the infl ammatory process. Biochem Soc Trans. 2007; 35 (2): 281-283.
20. Ueno M, Maeno T, Nomura M, et al. Hypoxia-inducible factor-1alpha mediates TGF-beta-induced PAI-1 production in alveolar macrophages in pulmonary fi brosis. Am J Physiol Lung Cell Mol Physiol. 2011; 300 (5): L740-L752.
21. Osoata GO, Hanazawa T, Brindicci C, et al. Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest. 2009; 135 (6): 1513-1520.
22. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax. 2003; 58 (7): 585-588.
23. Mercken EM, Hageman GJ, Schols AM, Akkermans MA, Bast A, Wouters EF. Rehabilitation decreases exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172 (8): 994-1001.
24. Rahman I, van Schadewijk AA, Crowther AJ, et al. 4-Hydroxy-2-nonenal, a specifi c lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166 (4): 490-495.
25. Caramori G, Romagnoli M, Casolari P, et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax. 2003; 58 (4): 348-351.
26. Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-infl ammatory effects of steroids during exacerbations of COPD. Thorax. 2009; 64 (5): 424-429.
27. Di Stefano A, Caramori G, Oates T, et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J. 2002; 20 (3): 556-563.
28. Iwasaki H, Okamoto R, Kato S, et al. High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rhokinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis. 2008; 196 (1): 22-28.
29. Ruiz-Ortega M, Esteban V, Egido J. The regulation of the infl ammatory response through nuclear factor-kappab pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Trends Cardiovasc Med. 2007; 17 (1): 19-25.
30. Swiatkowska M, Szemraj J, Cierniewski CS. Induction of PAI-1 expression by tumor necrosis factor alpha in endothelial cells is mediated by its responsive element located in the 4G/5G site. FEBS J. 2005; 272 (22): 5821-5831.
31. Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation. 1999; 100 (13): 1369-1373.
32. Kastl SP, Speidl WS, Kaun C, et al. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation. J Thromb Haemost. 2006; 4 (8): 1790-1797.
33. Hou B, Eren M, Painter CA, et al. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem. 2004; 279 (18): 18127-18136.
34. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996; 153 (2): 530-534.
35. Vernooy JH, Küçükaycan M, Jacobs JA, et al. Local and systemic infl ammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 2002; 166(9): 1218-1224.
36. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23 (12): 2369-2380.
37. Ito K, Charron CE, Adcock IM. Impact of protein acetylation in infl ammatory lung diseases. Pharmacol Ther. 2007; 116 (2): 249-265.
38. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005; 352 (19): 1967-1976.
39. Ito K, Hanazawa T, Tomita K, Barnes PJ, Adcock IM. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun. 2004; 315 (1): 240-245.
40. Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 2002; 21 (23): 6539-6548.
41. Montuschi P, Currò D, Ragazzoni E, Preziosi P, Ciabattoni G. Anaphylaxis increases 8-iso-prostaglandin F2alpha release from guinea-pig lung in vitro. Eur J Pharmacol. 1999; 365 (1): 59-64.
42. Milne GL, Sanchez SC, Musiek ES, Morrow JD. Quantifi-cation of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc. 2007; 2 (1): 221-226.